JAK2 and myeloproliferative neoplasm: Therefore, the management of low positive JAK2 V617F patients needs to be individualized based on their age, other comorbidities, having risk factors for thrombosis, etc. In this study, within the low-level mutation burden group (<3% of JAK2 V617F), we found one case of CHIP and three patients did not have MPN.